(RTTNews) - Sandoz, the generics and biosimilars division of Swiss drug major Novartis AG (NVS), said Monday that the European Commission granted marketing authorization in the European Union for a citrate-free high concentration formulation (HCF; 100 mg/mL) of its biosimilar Hyrimoz (adalimumab).
The approval includes all indications covered by the reference medicine: rheumatic diseases, Crohn's disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa.
The company noted that the adalimumab citrate-free HCF (100 mg/mL) formulation offers a 50 percent reduction in injection volume compared to the 50 mg/ml concentration and potentially decreases the number of injections required for patients who need 80 mg/mL or higher dosing.
Recently, US Food and Drug Administration also approved the citrate-free HCF of Hyrimoz (adalimumab-adaz) injection.
For More Such Health News, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
